Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailPlace de la radiotherapie dans le traitement du cancer du sein. Indications actuelles et perspectives
Meyns, Mia ULg; Jansen, Nicolas ULg; Deneufbourg, Jean-Marie ULg

in Revue Médicale de Liège (2006), 61(9), 623-31

Radiotherapy is an important part of breast cancer treatment. After breast conserving surgery, a dose of 50 Grays (Gy) is administered to the entire breast. Boost by external radiotherapy or brachytherapy ... [more ▼]

Radiotherapy is an important part of breast cancer treatment. After breast conserving surgery, a dose of 50 Grays (Gy) is administered to the entire breast. Boost by external radiotherapy or brachytherapy improves local control especially for women under fifty. For lobular in situ lesions, no additional treatment is required, while intraductal lesions are treated with post-operative radiotherapy in case of Van Nuys score of 7, 8 or 9. After mastectomy, irradiation is proposed in case of skin involvement, invasion of pectoral muscle, positivity of at least 3 axillary lymph nodes, SBR III grade, T3 stage or multifocality where the sum of tumour diameters are >5 cm. Irradiation of the axilla has become exceptional. In node positive patients, the supraclavicular region receives 50 Gy with low energy photons, whereas the internal mammary chain is treated at the same dose but half is administered by low energy photons et half by electrons. Exclusive or preoperative irradiation is rare, because of new chemotherapy schedules, new drugs and hormonotherapy developments. Neoadjuvant chemotherapy enhances possibilities of conservative surgery it is followed by radiotherapy depending on the same indiciations listed above. Re-irradiation is possible but one must be aware of the higher risk of late toxicity. Nowadays, major side-effects are rare but close follow-up during and after treatment is required from the radiation oncologist to detect, evaluate, prevent and even treat possible complications. [less ▲]

Detailed reference viewed: 209 (1 ULg)
Full Text
Peer Reviewed
See detailLa place de la recherche scientifique dans le tissu social
Laitat, E.; Marcoen, Jean Marie ULg

in Terre wallonne - Humains admis (2004), 8(2), 67-69

Detailed reference viewed: 5 (0 ULg)
Full Text
See detailPlace de la soie de landibe dans l’économie rurale de la région d’Arivonimamo
Diez, Lise; Poncelet, Marc ULg; Rakotoniaina, Naritiana et al

in Verheggen, François; Bogaert, Jan; Haubruge, Eric (Eds.) Les vers à soie malgaches : Enjeux écologiques et socio-économiques (2013)

Wild silk in Madagascar is produced by endemic silk moths of the genus Borocera, locally named landibe. Wild silk is used to produce shrouds and clothes, and provides a great added value. In this document ... [more ▼]

Wild silk in Madagascar is produced by endemic silk moths of the genus Borocera, locally named landibe. Wild silk is used to produce shrouds and clothes, and provides a great added value. In this document, we describe the silk sector in the Arivinimamo region, and we analyze the importance of silk production and transformation as a source of income for rural populations, as observed in 2008. First, the harvest of cocoons does not require any investment and weaving pays more than working as a field hand. In the study area, wild silk brings significant profits to households. In Antananarivo, workshops employ many weavers. Consequently, wild silk is quite important for the region’s employment. However, these activities still belong to the informal sector and it is quite difficult to know the real impact of the sector on the national economy. Wild silk products are mostly sold in Antananarivo, at outdoor marketplaces or in specialized shops. Nowadays, the principal problem of the wild silk enterprise is finding markets. The economic crisis in the country diminishes demand as well as investment possibilities for weavers and enterprises. [less ▲]

Detailed reference viewed: 26 (3 ULg)
Full Text
Peer Reviewed
See detailLa place de la supervision en thérapie cognitive et comportementale en Europe
Pomini, Valentino; Blairy, Sylvie ULg; Douilliez, Céline et al

in Revue Francophone de Clinique Comportementale et Cognitive (2011), XVI(3), 48-67

Detailed reference viewed: 52 (0 ULg)
See detailPlace de la thérapie active de reconditionnement à l’effort aérobie chez le patient fibromyalgique
Maquet, Didier ULg; Croisier, Jean-Louis ULg; Crielaard, Jean-Michel ULg

in Actes du Symposium « Kinésithérapie passive ou active » de la Fédération Nationale des Docteurs et Licenciés en Kinésithérapie (2003)

Detailed reference viewed: 29 (1 ULg)
Full Text
Peer Reviewed
See detailPlace de la tomographie d'émission de positons dans le suivi thérapeutique du cancer du sein
Jerusalem, Guy ULg; Belhocine, Tarik; Silvestre, Rose-Marie et al

in Médecine Nucléaire : Imagerie Fonctionnelle et Métabolique (2001), 25(6), 341-346

La tomographie à émission de positons (TEP) au 18F-fluorodeoxyglucose (FDG) fait l'objet d'un nombre croissant d'applications cliniques en oncologie surtout dans le bilan d'extension et le bilan de fin de ... [more ▼]

La tomographie à émission de positons (TEP) au 18F-fluorodeoxyglucose (FDG) fait l'objet d'un nombre croissant d'applications cliniques en oncologie surtout dans le bilan d'extension et le bilan de fin de traitement. Un domaine très prometteur mais peu étudié est l'utilisation de la TEP dans l'évaluation thérapeutique précoce. Nous passons en revue les données de la littérature concernant la place de la TEP dans l'évaluation précoce de la réponse thérapeutique chez des patientes atteintes de cancer du sein. La TEP permet d'identifier précocement les patientes qui ont une grande probabilité de présenter une réponse tumorale facorable à une chimiothérapie néoadjuvante (chimiothérapie première). Cependant, non propres travaux chez des patientes atteintes de cancer du sein métastatique sont moins prometteurs. La poursuite des travaux de recherche est indispensable pour mieux connaître le bénéfice réel et les limites d'une évaluation thérapeutique précoce. [less ▲]

Detailed reference viewed: 34 (3 ULg)
Full Text
Peer Reviewed
See detailLa place de la transplantation pancreatique dans le traitement du diabete
De Roover, Arnaud ULg; Detry, Olivier ULg; Coimbra Marques, Carla ULg et al

in Revue Médicale de Liège (2005), 60(5-6, May-Jun), 350-4

Pancreas transplantation has now become an established option in the treatment of diabetic complications. It normalizes glucose metabolism, prevents, stabilizes and improves the evolution of diabetes ... [more ▼]

Pancreas transplantation has now become an established option in the treatment of diabetic complications. It normalizes glucose metabolism, prevents, stabilizes and improves the evolution of diabetes-associated lesions. Improvements in surgical procedure and in immunosuppression have better defined its indications. Combined kidney-pancreas transplantation appears today as the best treatment for the diabetic patient with end stage renal disease. Isolated pancreas transplantation is reserved to non-uremic patients with severe diabetic complications or with hyperlabile glycaemic control and severe impairment of quality of life. [less ▲]

Detailed reference viewed: 85 (16 ULg)
Full Text
Peer Reviewed
See detailLa place de la vaccination en élevage bovin
Pastoret, Paul-Pierre ULg; Thiry, Etienne ULg; Baranowski, Eric

in Point Vétérinaire (1992), 24

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailPlace des anticorps monoclonaux dans le traitement des tumeurs de la tete et du cou.
Sautois, Brieuc ULg; Martin, Marie ULg; Demez, Pierre ULg et al

in Revue Médicale de Liège (2009), 64(5-6), 284-6

Monoclonal antibodies are now part of the armamentarium available for the treatment of head and neck cancer. Cetuximab, a monoclonal antibody targeting EGFR, improves overall survival as compared with ... [more ▼]

Monoclonal antibodies are now part of the armamentarium available for the treatment of head and neck cancer. Cetuximab, a monoclonal antibody targeting EGFR, improves overall survival as compared with radiotherapy alone as radical treatment of locally advanced head and neck cancer. It is now reimbursed in Belgium after multidisciplinary discussion if cisplatin is contra-indicated. In the metastatic setting adding cetuximab to platinum based chemotherapy improves overall survival as compared with chemotherapy alone, a first-time event over a 30-year period, unfortunately not yet accessible to the Belgian patients. Other monoclonal antibodies targeting EGFR or VEGF are also currently under investigation while cetuximab is being explored in the induction, the maintenance or the post-operative radiotherapy settings. [less ▲]

Detailed reference viewed: 61 (7 ULg)
Peer Reviewed
See detailLa place des bisphosphonates dans le traitement de l’ostéoporose
Reginster, Jean-Yves ULg

in Lettre du Rhumatologue (La) (1996), 222

Detailed reference viewed: 2 (2 ULg)
Full Text
See detailLa place des droits fondamentaux dans la construction européenne
Defossez, Alexandre ULg

Learning material (2013)

Detailed reference viewed: 114 (35 ULg)
Full Text
See detailLa place des droits fondamentaux dans la construction européenne
Defossez, Alexandre ULg

Learning material (2012)

Detailed reference viewed: 133 (26 ULg)
Full Text
See detailLa place des Eglises de réveil dans les accusations de sorcellerie portées sur enfants en RDC
Demart, Sarah ULg

in Enfants accusés de sorcellerie (2011, December)

Detailed reference viewed: 24 (2 ULg)
See detailPlace des examens d'urine dans la biologie clinique actuelle
Chapelle, Jean-Paul ULg; Melin, Pierrette ULg; Philippe, M.

Conference (2000, February 10)

Detailed reference viewed: 4 (0 ULg)
Full Text
Peer Reviewed
See detailPlace des fibrates dans le traitement de patients avec une dyslipidemie atherogene.
Ducobu, J.; Scheen, André ULg; Legat, P. et al

in Revue Médicale de Liège (2009), 64(10), 512-8

The demography of dyslipidemia has changed towards a more complex atherogenic dyslipidemia involving increased levels of LDL cholesterol, in particular highly atherogenic small dense particles ... [more ▼]

The demography of dyslipidemia has changed towards a more complex atherogenic dyslipidemia involving increased levels of LDL cholesterol, in particular highly atherogenic small dense particles, hypertriglyceridemia and low HDL cholesterol, together with increased levels of markers of inflammation, thrombogenesis and endothelial dysfunction. Statins were shown to significantly lower cardiovascular morbidity and mortality, but treated patients are still left with a high residual risk, in particular for those with metabolic syndrome, type 2 diabetes, or low HDL cholesterol levels. Fibrates have been shown to reduce plasma triglycerides and increase HDL cholesterol, while improving inflammation, thrombogenesis and endothelial dysfunction. Clinical trials with fibrates have demonstrated their potential to reduce cardiovascular morbidity and mortality too, often through other mechanisms than those of statins. Combination trials of statins with fibrates have shown a more complete improvement of lipid profile and risk markers than each class separately. In contrast with gemfibrozil, fenofibrate does not interact significantly with the pharmacokinetics of statins, and its combination with statins has been shown to have a low risk of muscular side-effects or liver toxicity. The ACCORD outcome trial is exploring possible benefits of the combination of fenofibrate with statins on morbidity and mortality of patients with type 2 diabetes. [less ▲]

Detailed reference viewed: 124 (10 ULg)